Literature DB >> 35176233

The switch from client holding to folding in the Hsp70/Hsp90 chaperone machineries is regulated by a direct interplay between co-chaperones.

Vinay Dahiya1, Daniel Andreas Rutz1, Patrick Moessmer2, Moritz Mühlhofer1, Jannis Lawatscheck1, Matthias Rief2, Johannes Buchner3.   

Abstract

Folding of stringent clients requires transfer from Hsp70 to Hsp90. The co-chaperone Hop physically connects the chaperone machineries. Here, we define its role from the remodeling of Hsp70/40-client complexes to the mechanism of client transfer and the conformational switching from stalled to active client-processing states of Hsp90. We show that Hsp70 together with Hsp40 completely unfold a stringent client, the glucocorticoid receptor ligand-binding domain (GR-LBD) in large assemblies. Hop remodels these for efficient transfer onto Hsp90. As p23 enters, Hsp70 leaves the complex via switching between binding sites in Hop. Current concepts assume that to proceed to client folding, Hop dissociates and the co-chaperone p23 stabilizes the Hsp90 closed state. In contrast, we show that p23 functionally interacts with Hop, relieves the stalling Hsp90-Hop interaction, and closes Hsp90. This reaction allows folding of the client and is thus the key regulatory step for the progression of the chaperone cycle.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hop; Hsp70; Hsp90; TPR domains; chaperone networks; client transfer; glucocorticoid receptor; optical trap; p23; protein folding

Mesh:

Substances:

Year:  2022        PMID: 35176233     DOI: 10.1016/j.molcel.2022.01.016

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  5 in total

Review 1.  Hsp90 and Associated Co-Chaperones of the Malaria Parasite.

Authors:  Tanima Dutta; Harpreet Singh; Adrienne L Edkins; Gregory L Blatch
Journal:  Biomolecules       Date:  2022-07-22

2.  Stress-inducible phosphoprotein 1 (HOP/STI1/STIP1) regulates the accumulation and toxicity of α-synuclein in vivo.

Authors:  Rachel E Lackie; Aline S de Miranda; Mei Peng Lim; Vladislav Novikov; Nimrod Madrer; Nadun C Karunatilleke; Benjamin S Rutledge; Stephanie Tullo; Anne Brickenden; Matthew E R Maitland; David Greenberg; Daniel Gallino; Wen Luo; Anoosha Attaran; Irina Shlaifer; Esther Del Cid Pellitero; Caroline Schild-Poulter; Thomas M Durcan; Edward A Fon; Martin Duennwald; Flavio H Beraldo; M Mallar Chakravarty; Timothy J Bussey; Lisa M Saksida; Hermona Soreq; Wing-Yiu Choy; Vania F Prado; Marco A M Prado
Journal:  Acta Neuropathol       Date:  2022-09-19       Impact factor: 15.887

Review 3.  Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations.

Authors:  Fuping Wang; Haotian Zhang; Haitao Wang; Tian Qiu; Binghong He; Qiong Yang
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

4.  There are more Hsp90 chaperone mechanisms in heaven and earth, dear reader, than are dreamt of in your philosophy.

Authors:  Eugenia M Clerico; Lila M Gierasch
Journal:  Mol Cell       Date:  2022-04-21       Impact factor: 19.328

Review 5.  Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer.

Authors:  Sarah J Backe; Rebecca A Sager; Katherine A Meluni; Mark R Woodford; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Biomolecules       Date:  2022-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.